| Literature DB >> 29207890 |
Edith L Pfister1, Natalie DiNardo1, Erica Mondo2, Florie Borel3, Faith Conroy1, Cara Fraser4, Gwladys Gernoux3, Xin Han5, Danjing Hu5, Emily Johnson1,6, Lori Kennington1, PengPeng Liu5, Suzanne J Reid7, Ellen Sapp8, Petr Vodicka8,9, Tim Kuchel4, A Jennifer Morton10, David Howland11, Richard Moser12, Miguel Sena-Esteves3, Guangping Gao3, Christian Mueller3,13, Marian DiFiglia8, Neil Aronin1,14.
Abstract
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT, but evidence for their effectiveness and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT with 73 CAG repeats. AAV9 was used to deliver unilaterally to HD sheep striatum an artificial miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters: U6 or CβA. The treatment reduced human mutant (m) HTT mRNA and protein 50-80% in the striatum at 1 and 6 months post injection. Silencing was detectable in both the caudate and putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant loss of neurons labeled by DARPP32 or NeuN at 6 months after treatment, and Iba1-positive microglia were detected at control levels. It is concluded that safe and effective silencing of human mHTT protein can be achieved and sustained in a large-animal brain by direct delivery of an AAV carrying an artificial miRNA.Entities:
Keywords: AAV; Huntington's disease; RNAi; large animal models
Mesh:
Substances:
Year: 2018 PMID: 29207890 PMCID: PMC6909722 DOI: 10.1089/hum.2017.199
Source DB: PubMed Journal: Hum Gene Ther ISSN: 1043-0342 Impact factor: 5.695